SequelSEC

Advanced Biomed Inc. ADVB

Services-Medical Laboratories · CIK 0001941029 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$127.64K
Fiscal year ended 2026-06-30
Operating income
-$6.23M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$4.43MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.20Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity1.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Medical Laboratories filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio9.33x28th

Advanced Biomed Inc. (ADVB) reported revenue of $127.64K and net income of $6.68M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Advanced Biomed Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

Advanced Biomed Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$127.64K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$6.23M
Net income$6.68M
Research & developmentUnavailable
Weighted-average diluted sharesshares 1.25M
Pretax income-$6.26M
Income tax expense-$1.20K
Diluted EPS$5.33
Selling, general & administrativeUnavailable
General & administrative$4.63M
Selling & marketingUnavailable

Balance

Advanced Biomed Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$13.75M
Current assets$13.75M
Total liabilities$1.47M
Current liabilities$1.47M
Total equity incl. NCI$12.28M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Advanced Biomed Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$1.95M
Capital expendituresUnavailable
Investing cash flow-$2.51M
Financing cash flow$1.97M
Net change in cash-$2.52M
Stock-based compensation$1.73M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Advanced Biomed Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-4883.8%
FCF marginUnavailable
SBC / revenue1358.5%
Current ratio9.33x
Revenue YoY growthUnavailable
Net margin5231.3%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ADVB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-10-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-K · Filed 2025-10-08View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ACON AMS BDSX BGLC BLLN CAI CDNA CELC CFOR CSTL DGX FCHS

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.